Galecto Inc (GLTO) - Net Assets
Based on the latest financial reports, Galecto Inc (GLTO) has net assets worth $510.26 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($535.44 Million) and total liabilities ($25.18 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check GLTO goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $510.26 Million |
| % of Total Assets | 95.3% |
| Annual Growth Rate | 34.2% |
| 5-Year Change | 105.06% |
| 10-Year Change | N/A |
| Growth Volatility | 498.78 |
Galecto Inc - Net Assets Trend (2018–2025)
This chart illustrates how Galecto Inc's net assets have evolved over time, based on quarterly financial data. See Galecto Inc liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Galecto Inc (2018–2025)
The table below shows the annual net assets of Galecto Inc from 2018 to 2025. For live valuation and market cap data, see how much is Galecto Inc worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $240.38 Million | +1418.41% |
| 2024-12-31 | $15.83 Million | -51.03% |
| 2023-12-31 | $32.33 Million | -47.64% |
| 2022-12-31 | $61.75 Million | -47.32% |
| 2021-12-31 | $117.22 Million | -29.17% |
| 2020-12-31 | $165.49 Million | +241.42% |
| 2019-12-31 | $48.47 Million | +58.09% |
| 2018-12-31 | $30.66 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Galecto Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 45434600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Comprehensive Income | $802.00K | 0.33% |
| Other Components | $726.94 Million | 302.41% |
| Total Equity | $240.38 Million | 100.00% |
Galecto Inc Competitors by Market Cap
The table below lists competitors of Galecto Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Kemper Corporation
NYSE:KMPR
|
$1.47 Billion |
|
Jiangsu Zhangjiagang Rural Commercial Bank Co Ltd
SHE:002839
|
$1.47 Billion |
|
La-Z-Boy Incorporated
NYSE:LZB
|
$1.47 Billion |
|
Southern Publishing&Media Co
SHG:601900
|
$1.47 Billion |
|
Sayona Mining Limited American Depository Shares
NASDAQ:ELVR
|
$1.47 Billion |
|
Hisense Home Appliances Group Co. Ltd
F:GKE
|
$1.47 Billion |
|
Deutsche EuroShop AG
F:DEQ
|
$1.47 Billion |
|
China Resources Chemical Innovative Materials Co. Ltd.
SHE:301090
|
$1.47 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Galecto Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 15,831,000 to 240,380,000, a change of 224,549,000 (1418.4%).
- Net loss of 209,839,000 reduced equity.
- New share issuances of 266,811,000 increased equity.
- Other comprehensive income increased equity by 705,000.
- Other factors increased equity by 166,872,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-209.84 Million | -87.29% |
| Share Issuances | $266.81 Million | +111.0% |
| Other Comprehensive Income | $705.00K | +0.29% |
| Other Changes | $166.87 Million | +69.42% |
| Total Change | $- | 1418.41% |
Book Value vs Market Value Analysis
This analysis compares Galecto Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.15x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 0.81x to 0.15x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $30.14 | $24.45 | x |
| 2019-12-31 | $47.64 | $24.45 | x |
| 2020-12-31 | $163.77 | $24.45 | x |
| 2021-12-31 | $116.01 | $24.45 | x |
| 2022-12-31 | $60.76 | $24.45 | x |
| 2023-12-31 | $30.42 | $24.45 | x |
| 2024-12-31 | $13.68 | $24.45 | x |
| 2025-12-31 | $164.40 | $24.45 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Galecto Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -87.29%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.08x
- Recent ROE (-87.29%) is below the historical average (-79.67%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | -51.76% | 0.00% | 0.00x | 1.14x | $-18.93 Million |
| 2019 | -79.26% | 0.00% | 0.00x | 1.17x | $-43.27 Million |
| 2020 | -21.05% | 0.00% | 0.00x | 1.04x | $-51.39 Million |
| 2021 | -44.15% | 0.00% | 0.00x | 1.04x | $-63.47 Million |
| 2022 | -99.79% | 0.00% | 0.00x | 1.19x | $-67.80 Million |
| 2023 | -118.61% | 0.00% | 0.00x | 1.18x | $-41.58 Million |
| 2024 | -135.42% | 0.00% | 0.00x | 1.08x | $-23.02 Million |
| 2025 | -87.29% | 0.00% | 0.00x | 1.08x | $-233.88 Million |
Industry Comparison
This section compares Galecto Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $115,651,619
- Average return on equity (ROE) among peers: -486.20%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Galecto Inc (GLTO) | $510.26 Million | -51.76% | 0.05x | $1.47 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $85.57 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $681.00K | -3192.95% | 12.43x | $328.21 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $366.11 Million | -27.58% | 0.16x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $203.00 Million | -189.21% | 0.36x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $-1.24 Million | 0.00% | 0.00x | $35.10 Million |
| Abivax SA American Depositary Shares (ABVX) | $7.19 Million | -844.90% | 9.51x | $7.90 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $335.29 Million | -86.32% | 0.15x | $3.66 Billion |
About Galecto Inc
Damora Therapeutics, Inc., a clinical-stage biotechnology company, develops molecule therapeutics for the treatment of fibrosis, cancer, inflammation, and other related diseases. It develops GB3226, a preclinical small molecule dual inhibitor of ENL-YEATS and FLT3 and GB1211, an oral small molecule inhibitor of galectin-3 to treat multiple types of oncology and liver disease indications. The comp… Read more